Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Drug ID: DAP001372

Drug Information
NameEbselen
SynonymsNCGC00024072-03; 1,2-Benzisoselenazol-3(2H)-one, 2-phenyl-; Ebselenum [Latin]; NCGC00178610-01; E 3520; SPBio_001301; MLS001148646; Ebseleno; KBio2_002630; C13H9NOSe; Prestwick3_000740; NCGC00015412-13; CAS-60940-34-3; KBio2_005198; HMS502P13; NINDS_000951; HMS1570C22; NCGC00015412-03; PZ51; BCBcMAP01_000149; PZ 51; NCGC00024072-04; CID3194; ebselen; AC-1124; 2-Phenyl-1,2-benzisoselenazolin-3-one; Spectrum4_000445; RP 60931; CPD000058445; EU-0100541; AC1L1FDW; UNII-40X2P7DPGH; Prestwick0_000740; NCGC00015412-01; Bio2_000542; CHEBI:175507; 2-Phenyl-1,2-benzisoselenazol-3(2H)-one; KBioGR_000062; HMS2052N09; Spectrum3_000799; Lopac0_000541; HMS1989D04; Ebselene; SAM001247071; BSPBio_001342; Harmokisane; BSPBio_002538; Spectrum5_001713; AB00053217; QTL1_000035; HMS1361D04; nchembio.109-comp1; BPBio1_000770; Ebseleno [Spanish]; IDI1_000951; DivK1c_000951; BRD-K29359156-001-06-1; Prestwick2_000740; SMR000058445; Prestwick_1057; DR 3305; I09-1611; Prestwick1_000740; BSPBio_000700; Ebselen [INN]; PZ-51; CHEMBL51085; NSC 639762; CCRIS 3714; Ebselenum; NCGC00015412-06; HMS1791D04; 2-phenyl-1,2-benzoisoselenazol-3(2H)-one; SPI-3005; LS-33527; MLS000028488; KBio3_000124; Bio2_000062; NCGC00024072-05; MLS-0003066.0001; Ebselene [French]; Spectrum2_001441; NCGC00178610-03; 60940-34-3; KBio2_000062; SPI-1005; KBioGR_000830; KBio3_000123; E3520_SIGMA; SPBio_002639; NSC639762; DR-3305; NCGC00178610-02; C042986; KBio3_001758; NCGC00015412-02; KBio1_000951; KBioSS_000062; Lopac-E-3520; IDI1_033812; 2-phenyl-1,2-benzoselenazol-3-one
IndicationReperfusion injury and stroke
[ICD9: 410, 434.91   ICD10: I21, I22, I61-I63]
Approved    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
InChI1S/C13H9NOSe/c15-13-11-8-4-5-9-12(11)16-14(13)10-6-2-1-3-7-10/h1-
9H
InChIKeyDYEFUKCXAQOFHX-UHFFFAOYSA-N
Canonical SMILESC1=CC=C(C=C1)N2C(=O)C3=CC=CC=C3[Se]2    
Therapeutic ClassFibrinolytic Agents
CAS NumberCAS 60940-34-3
FormulaC13H9NOSe
PubChem Compound IDCID 3194.
PubChem Substance IDSID 183892.
TargetSerum albuminBinder[2]
Ref 1Advances in ischemic stroke treatment: neuroprotective and combination therapies. Expert Opin Emerg Drugs. 2007 Mar;12(1):97-112. To Reference
Ref 2Transport of ebselen in plasma and its transfer to binding sites in the hepatocyte. Biochem Pharmacol. 1994 Sep 15;48(6):1137-44. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543